Fed. Circ. Panel Backs Invalidation Of OxyContin Patent
The Federal Circuit on Monday upheld a Delaware federal court's decision that deemed invalid a Purdue Pharma patent covering an abuse-deterrent version of the opioid OxyContin, rebuffing the company's arguments that...To view the full article, register now.
Already a subscriber? Click here to view full article